Coreline Soft Supplies AVIEW LCS Plus to Geneva Radiology Hub CIMC

Coreline Soft (CEO: Jin Kuk Kim) has signed an agreement to supply its AI-powered chest imaging analysis solution, AVIEW LCS Plus, to the Centre d’Imagerie Médicale de Cornavin (CIMC), a leading radiology hub in Geneva, Switzerland.

Located in the heart of Geneva, CIMC is a state-of-the-art imaging center staffed by experienced radiologists and equipped with advanced diagnostic technologies such as high-resolution CT and MRI, delivering precision medical services to patients.

This adoption marks a strategic milestone for the Medbase Group, to which CIMC belongs. As Medbase expands its radiology center network across Switzerland, Coreline’s AI solution is expected to establish itself as a standardized early-detection platform across the group.
 

AVIEW LCS Plus: 3-in-1 AI Solution
Coreline Soft’s AVIEW LCS Plus can simultaneously and automatically analyze lung cancer (nodules), emphysema, and coronary artery calcification from a single low-dose chest CT scan. The solution has obtained both MDR and CE certification, ensuring full compliance with Europe’s stringent regulatory standards.

Given that Medbase imaging centers operate with a screening-focused model and higher patient throughput compared to general hospitals, the introduction of AI-driven automation such as AVIEW LCS Plus is projected to deliver particularly strong ROI (return on investment).

Expanding Public and Private References in Switzerland
Switzerland ranks among the top OECD countries for lung cancer mortality, and interest in AI-enabled early detection programs has been rising rapidly. Building on its 2024 collaboration with CHUV Lausanne—the nation’s largest university hospital—Coreline Soft has accelerated its entry into Switzerland’s private lung cancer screening market.

The CIMC contract follows successes in Germany, France, and the UK, and adds another strategic foothold in Switzerland. Coreline Soft stated, “By securing key references across both public and private sectors, we expect to further accelerate adoption of our solutions in Switzerland and reinforce our leadership in the AI-driven early detection market for lung and cardiovascular disease across Europe.”